212 related articles for article (PubMed ID: 31121195)
1. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
[TBL] [Abstract][Full Text] [Related]
2. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
4. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
[TBL] [Abstract][Full Text] [Related]
5. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
[TBL] [Abstract][Full Text] [Related]
8. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.
Peraldo-Neia C; Ostano P; Cavalloni G; Pignochino Y; Sangiolo D; De Cecco L; Marchesi E; Ribero D; Scarpa A; De Rose AM; Giuliani A; Calise F; Raggi C; Invernizzi P; Aglietta M; Chiorino G; Leone F
BMC Genomics; 2018 Jun; 19(1):440. PubMed ID: 29871612
[TBL] [Abstract][Full Text] [Related]
10. Mutation of
Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
[No Abstract] [Full Text] [Related]
11. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Grassian AR; Pagliarini R; Chiang DY
Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
[TBL] [Abstract][Full Text] [Related]
12. Platinum Sensitivity in
Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
[TBL] [Abstract][Full Text] [Related]
13. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
[TBL] [Abstract][Full Text] [Related]
14. IDH mutations in liver cell plasticity and biliary cancer.
Saha SK; Parachoniak CA; Bardeesy N
Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
[TBL] [Abstract][Full Text] [Related]
15. IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma.
Zhu Y; Kwong LN
Cancer Discov; 2022 Mar; 12(3):604-605. PubMed ID: 35257150
[TBL] [Abstract][Full Text] [Related]
16. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
[TBL] [Abstract][Full Text] [Related]
18. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
[TBL] [Abstract][Full Text] [Related]
19. IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Xiang X; Liu Z; Zhang C; Li Z; Gao J; Zhang C; Cao Q; Cheng J; Liu H; Chen D; Cheng Q; Zhang N; Xue R; Bai F; Zhu J
Adv Sci (Weinh); 2021 Sep; 8(17):e2101230. PubMed ID: 34250753
[TBL] [Abstract][Full Text] [Related]
20. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
